Vericel (VCEL) Q1 2026 earnings review
Accelerating Growth and Surging Profitability Drive a Clean Beat and Raise
Vericel delivered an exceptionally strong Q1, crushing historical seasonal weakness. Total revenue surged 30% YoY to $68.4 million, accelerating from the 23% growth seen in Q4 2025. The core MACI franchise grew 22%, fueled by the MACI Arthro rollout, while the Burn Care segment staged a massive reversal with 91% growth. More importantly, the company proved it can scale efficiently: despite absorbing costs for a recently expanded sales force and a new manufacturing facility, Adjusted EBITDA skyrocketed 195% and Free Cash Flow turned highly positive ($15.1M). Management confidently raised full-year top-line guidance across all segments.
🐂 Bull Case
MACI achieved 20%+ revenue growth for the fourth consecutive quarter. Record Q1 biopsies and surgeons taking biopsies prove the less-invasive MACI Arthro instrument is successfully driving deeper market penetration.
Epicel revenue reversed its prior-year struggles, jumping 119% YoY. A newly announced $197M BARDA contract for NexoBrid injects massive, non-commercial upside into the Burn Care franchise.
🐻 Bear Case
Despite the BARDA headline, NexoBrid's core commercial revenue actually decelerated, falling to $1.1 million from $1.3 million a year ago, raising questions about standard clinical adoption.
Total operating expenses rose 17% YoY to $57.3 million. While currently masked by 30% revenue growth, the structural costs of the 30% sales force expansion and new Burlington facility will pressure margins if volume falters.
⚖️ Verdict: 🟢
Bullish. The combination of accelerating top-line growth, expanding profit margins, a guidance raise, and a massive government contract sets up a highly favorable risk/reward profile for the rest of 2026.
Key Themes
MACI Arthro is Accelerating Core Growth
The MACI franchise delivered $56.4 million in Q1 (+22% YoY). The growth algorithm remains highly intact: Vericel reported record Q1 MACI biopsies, implants, and implanting surgeons. By training roughly 1,000 surgeons on the less-invasive MACI Arthro procedure over the past year, the company is capturing smaller defect cases (e.g., small condyle) that were previously treated with standard microfracture. This is driving a sustainable, accelerating volume trend.
Burn Care Segment Reversing
Burn Care revenue surged 91% to $12.0 million, completely reversing the narrative from Q1 2025 when the segment was plagued by high case cancellation rates. Epicel was the standout, with revenue skyrocketing 119% to $10.9 million. This proves the franchise's volatility can swing violently in both directions, and management has clearly regained control of the commercial execution here.
$197 Million BARDA Contract De-risks NexoBrid
Management announced a landmark BARDA award valued at up to $197 million for the procurement and advanced development of NexoBrid. This is a game-changer for the Burn Care segment, providing a massive, guaranteed revenue floor independent of the volatile commercial hospital market. It effectively de-risks the NexoBrid asset.
NexoBrid Commercial Revenue Decelerating
Buried beneath the BARDA announcement and the Epicel surge is a concerning data point: NexoBrid net revenue came in at just $1.1 million, a contraction from $1.3 million in Q1 2025. Given management's previous focus on deep penetration across 90 target accounts, this YoY deceleration implies that standard clinical utilization is struggling to gain traction.
Operating Expenses Marching Higher
Total operating expenses increased from $49.1 million to $57.3 million. Management attributes this to headcount additions (specifically the 30% MACI sales force expansion executed in late 2025) and costs related to the new Burlington facility. While the 30% revenue growth currently outpaces this 17% OpEx growth, maintaining operating leverage will require flawless execution on volume moving forward.
Other KPIs
Accelerating dramatically from $3.2 million a year ago. The Adjusted EBITDA margin expanded from 6% to 14% YoY. This proves the company's business model is highly scalable; adding incremental revenue dollars flows directly to the bottom line despite ongoing facility and sales investments.
Reversing forcefully from negative -$7.6 million in Q1 2025. The company generated $16.4 million in operating cash flow against just $1.3 million in CapEx (down from $14.2M in the prior year period as the Burlington facility construction wrapped up). The company now boasts $211 million in cash and zero debt.
Expanding. Up from 69% in the prior year period. Favorable product mix, higher Epicel volume, and fixed cost absorption are driving this improvement, keeping the company on track for its ~75% full-year target.
Guidance
Accelerating. Raised by $10 million from the prior $316 - $326 million range. The $331 million midpoint implies roughly 20% YoY growth compared to FY25's $276.3 million, confirming the momentum seen in Q1 is expected to persist.
Stable to Accelerating. Raised slightly from the previous $280 - $286 million range. The midpoint of $285 million implies ~19% YoY growth over FY25 ($239.5M), reflecting continued confidence in the Arthro rollout.
Accelerating. Dramatically raised from the previous $36 - $40 million range. The $46 million midpoint implies ~25% YoY growth over FY25's $36.8 million, driven by the structural turnaround in Epicel case scheduling.
Stable. Management reaffirmed this target, which sits just above FY25's 26% margin. This indicates that while gross margins are improving, the company is successfully reinvesting back into R&D (MACI Ankle) and SG&A.
Key Questions
NexoBrid Commercial Demand
Excluding the new BARDA contract, NexoBrid revenue declined YoY in Q1 to $1.1M. Is this due to ordering patterns and inventory timing, or are we seeing a genuine stall in clinical adoption among target hospitals?
BARDA Revenue Recognition
How should we model the timing and margin profile of the $197 million BARDA contract? Does the raised FY26 Burn Care guidance include any early procurement revenue from this award?
Burlington Facility Utilization
With the FDA approving commercial manufacturing at the new Burlington facility, what is the timeline to phase out older manufacturing lines, and how much gross margin upside remains once full consolidation is achieved?